JP2008520589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520589A5 JP2008520589A5 JP2007541601A JP2007541601A JP2008520589A5 JP 2008520589 A5 JP2008520589 A5 JP 2008520589A5 JP 2007541601 A JP2007541601 A JP 2007541601A JP 2007541601 A JP2007541601 A JP 2007541601A JP 2008520589 A5 JP2008520589 A5 JP 2008520589A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- compound
- amyloid
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 230000003941 amyloidogenesis Effects 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 210000004556 brain Anatomy 0.000 claims 10
- 230000003247 decreasing effect Effects 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 238000009825 accumulation Methods 0.000 claims 9
- 208000037259 Amyloid Plaque Diseases 0.000 claims 8
- 238000004220 aggregation Methods 0.000 claims 8
- 230000009286 beneficial effect Effects 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 230000002159 abnormal effect Effects 0.000 claims 7
- 230000002688 persistence Effects 0.000 claims 7
- 230000004845 protein aggregation Effects 0.000 claims 7
- 230000012846 protein folding Effects 0.000 claims 7
- 230000007082 Aβ accumulation Effects 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 206010002022 amyloidosis Diseases 0.000 claims 6
- -1 scyllo-inositol compound Chemical class 0.000 claims 6
- 230000008021 deposition Effects 0.000 claims 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 230000035508 accumulation Effects 0.000 claims 4
- 230000015556 catabolic process Effects 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 230000003920 cognitive function Effects 0.000 claims 4
- 238000006731 degradation reaction Methods 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 230000003977 synaptic function Effects 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 230000002490 cerebral effect Effects 0.000 claims 3
- 230000019771 cognition Effects 0.000 claims 3
- 230000002518 glial effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 230000027928 long-term synaptic potentiation Effects 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- 230000002035 prolonged effect Effects 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 239000000835 fiber Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000007483 microbial process Effects 0.000 claims 2
- 230000007171 neuropathology Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 230000006974 Aβ toxicity Effects 0.000 claims 1
- 208000037914 B-cell disorder Diseases 0.000 claims 1
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000014060 Niemann-Pick disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000017004 dementia pugilistica Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000011523 endocrine gland cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000027232 peripheral nervous system disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 208000008864 scrapie Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62884004P | 2004-11-17 | 2004-11-17 | |
| PCT/CA2005/001744 WO2006053428A1 (en) | 2004-11-17 | 2005-11-17 | Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012178707A Division JP2012214516A (ja) | 2004-11-17 | 2012-08-10 | シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520589A JP2008520589A (ja) | 2008-06-19 |
| JP2008520589A5 true JP2008520589A5 (enExample) | 2008-12-25 |
Family
ID=36406797
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007541601A Pending JP2008520589A (ja) | 2004-11-17 | 2005-11-17 | シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法 |
| JP2012178707A Pending JP2012214516A (ja) | 2004-11-17 | 2012-08-10 | シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012178707A Pending JP2012214516A (ja) | 2004-11-17 | 2012-08-10 | シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20060189582A1 (enExample) |
| EP (2) | EP1824496A4 (enExample) |
| JP (2) | JP2008520589A (enExample) |
| CN (2) | CN101102779A (enExample) |
| AU (1) | AU2005306531B2 (enExample) |
| BR (1) | BRPI0517733A (enExample) |
| CA (1) | CA2588423A1 (enExample) |
| MX (1) | MX2007005870A (enExample) |
| WO (1) | WO2006053428A1 (enExample) |
| ZA (1) | ZA200704872B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US8257680B1 (en) | 2004-02-24 | 2012-09-04 | The General Hospital Corporation | Catalytic radiofluorination |
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| JP2009511568A (ja) * | 2005-10-13 | 2009-03-19 | ワラタ ファーマシューティカルズ， インコーポレイテッド | イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用 |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| WO2007129221A2 (en) * | 2006-02-17 | 2007-11-15 | Waratah Parmaceuticals Inc | Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation |
| KR20090026247A (ko) * | 2006-03-09 | 2009-03-12 | 와라타 파마수티컬즈, 인크. | 단백질 응집 장애의 치료를 위한 사이클로헥산 폴리알콜 제형 |
| WO2008034244A1 (en) * | 2006-09-21 | 2008-03-27 | Waratah Pharmaceuticals Inc. | The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases |
| EP2091566A4 (en) * | 2006-11-24 | 2011-07-06 | Waratah Pharmaceuticals Inc | COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| WO2008124929A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES |
| CA2683580A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Treatment of amyotrophic lateral sclerosis |
| WO2008124930A1 (en) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases |
| HRP20130768T1 (en) * | 2007-04-12 | 2013-10-25 | Waratah Pharmaceuticals, Inc. | Use of cyclohexanehexol derivatives in the treatment of ocular diseases |
| US9006283B2 (en) * | 2007-07-12 | 2015-04-14 | Acumen Pharmaceuticals, Inc. | Methods of modifying amyloid β oligomers using non-peptidic compounds |
| US20110098309A1 (en) * | 2007-07-12 | 2011-04-28 | Acumen Pharmaceuticals, Inc. | Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds |
| US8962677B2 (en) * | 2007-07-12 | 2015-02-24 | Acumen Pharmaceuticals, Inc. | Methods of restoring cognitive ability using non-peptidic compounds |
| JP2010538611A (ja) * | 2007-09-07 | 2010-12-16 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | タウタンパク質スクリーニングアッセイ |
| AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
| EP3231804B1 (en) * | 2008-03-21 | 2021-03-03 | The General Hospital Corporation | Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders |
| CA2737163C (en) * | 2008-09-15 | 2019-03-12 | Elan Pharmaceuticals, Inc. | Methods of treatment of hyperuricemia and associated disease states |
| WO2010040232A1 (en) * | 2008-10-09 | 2010-04-15 | Waratah Pharmaceuticals Inc. | Use of scyllo-inositols for the treatment of macular degeneration-related disorders |
| US20110081428A1 (en) * | 2009-09-16 | 2011-04-07 | The Buck Institute For Age Research | Use of thioflavin-like compounds to increase life span and/or health span |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| US20140056901A1 (en) * | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4515722A (en) * | 1982-03-30 | 1985-05-07 | Merck & Co., Inc. | Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents |
| US4474806A (en) * | 1982-05-10 | 1984-10-02 | Merck & Co., Inc. | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents |
| IT1164225B (it) | 1983-05-13 | 1987-04-08 | Anic Spa | Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione |
| US4952396A (en) * | 1986-11-19 | 1990-08-28 | Linus Pauling Institute Of Science & Medicine | Method of using phytic acid for inhibiting tumor growth |
| US4758430A (en) * | 1987-01-21 | 1988-07-19 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| SE8904355D0 (sv) * | 1989-12-21 | 1989-12-21 | Perstorp Ab | Medicament |
| US5217959A (en) * | 1990-09-06 | 1993-06-08 | Robert Sabin | Method of treating multiple sclerosis with phytic acid |
| US5112814A (en) * | 1990-10-24 | 1992-05-12 | Robert Sabin | Method of treatment of Parkinson's disease using phytic acid |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| SE9102068L (sv) * | 1991-07-03 | 1993-01-04 | Perstorp Ab | Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav |
| SE9200547L (sv) * | 1992-02-25 | 1993-06-14 | Perstorp Ab | En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat |
| DE69332542T2 (de) * | 1992-10-05 | 2003-08-14 | Virginia Tech Intellectual Properties Inc., Blacksburg | Synthesen von d-chiro-3-inosose und (+)-d-chiro-inositol |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| DK0619369T3 (da) * | 1993-04-05 | 2003-10-06 | Aveve Nv | Phytathydrolyse og enzymsammensætning til hydrolyse af phytat |
| ES2130440T3 (es) * | 1993-08-11 | 1999-07-01 | Hokko Chem Ind Co | Proceso para producir d-(quiro)-inositol. |
| SE502574C2 (sv) * | 1994-01-25 | 1995-11-13 | Perstorp Ab | En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat |
| US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6232486B1 (en) * | 1996-06-11 | 2001-05-15 | Nutrimed Biotech | Molecular probes and modulators for PI-PLC and PI 3-kinase |
| US5977078A (en) * | 1996-09-20 | 1999-11-02 | The Regents Of The Univesity Of California | Inositol polyphosphate derivatives and methods of using same |
| US5880099A (en) * | 1996-09-20 | 1999-03-09 | The Regents Of The University Of California | Inositol polyphosphates and methods of using same |
| US5998485A (en) * | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| US6153603A (en) * | 1997-06-27 | 2000-11-28 | Perstorp Ab | Method of treating angiogenesis in tumor tissue |
| US6331891B1 (en) * | 1998-04-07 | 2001-12-18 | Fujitsu Limited | Apparatus and method for assembling semiconductor device and semiconductor device thus fabricated |
| US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| US6818430B1 (en) * | 1999-06-07 | 2004-11-16 | Hokko Chemical Industry Co., Ltd. | Process for producing L-epi-2-inosose and novel process for producing epi-inositol |
| US6329256B1 (en) * | 1999-09-24 | 2001-12-11 | Advanced Micro Devices, Inc. | Self-aligned damascene gate formation with low gate resistance |
| RU2002111408A (ru) * | 1999-10-18 | 2004-05-20 | Мусклетеч Ресеч Энд Девелопмент Инк. (Ca) | Пищевая добавка для увеличения мышечной массы и силы |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| DE10031955A1 (de) * | 2000-06-30 | 2002-01-17 | Deutsches Krebsforsch | Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel |
| US7060695B2 (en) * | 2001-02-06 | 2006-06-13 | Qlt, Inc. | Method to prevent vision loss |
| EP1357912B9 (en) * | 2001-02-06 | 2012-06-13 | QLT Inc. | Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration |
| US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| WO2003007944A1 (en) * | 2001-07-20 | 2003-01-30 | Qlt, Inc. | Treatment of macular edema with photodynamic therapy |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| KR101314079B1 (ko) | 2003-10-14 | 2013-10-04 | 혹꼬우 가가꾸 고오교오 가부시끼가이샤 | 실로-이노시톨의 제조방법 |
-
2005
- 2005-11-17 EP EP05808109A patent/EP1824496A4/en not_active Withdrawn
- 2005-11-17 ZA ZA200704872A patent/ZA200704872B/xx unknown
- 2005-11-17 CA CA002588423A patent/CA2588423A1/en not_active Abandoned
- 2005-11-17 CN CNA2005800467018A patent/CN101102779A/zh active Pending
- 2005-11-17 CN CN2013101874554A patent/CN103301094A/zh active Pending
- 2005-11-17 JP JP2007541601A patent/JP2008520589A/ja active Pending
- 2005-11-17 US US11/280,818 patent/US20060189582A1/en not_active Abandoned
- 2005-11-17 AU AU2005306531A patent/AU2005306531B2/en not_active Expired
- 2005-11-17 EP EP10000985A patent/EP2186518A1/en not_active Withdrawn
- 2005-11-17 US US11/667,822 patent/US20080306166A1/en not_active Abandoned
- 2005-11-17 MX MX2007005870A patent/MX2007005870A/es not_active Application Discontinuation
- 2005-11-17 BR BRPI0517733-2A patent/BRPI0517733A/pt not_active IP Right Cessation
- 2005-11-17 WO PCT/CA2005/001744 patent/WO2006053428A1/en not_active Ceased
-
2008
- 2008-05-22 US US12/125,498 patent/US20090062403A1/en not_active Abandoned
-
2010
- 2010-09-15 US US12/882,250 patent/US20110201694A1/en not_active Abandoned
-
2012
- 2012-08-10 JP JP2012178707A patent/JP2012214516A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520589A5 (enExample) | ||
| US20240082207A1 (en) | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | |
| EP3348556B1 (en) | Heteroaryl amides as inhibitors of protein aggregation | |
| JP2006522740A5 (enExample) | ||
| WO2007115306A2 (en) | Compounds for diseases and disorders | |
| JP2015521617A5 (enExample) | ||
| JP2013534256A5 (enExample) | ||
| KR20090026247A (ko) | 단백질 응집 장애의 치료를 위한 사이클로헥산 폴리알콜 제형 | |
| JP2019533642A5 (enExample) | ||
| CN104918951A (zh) | 多粘菌素、组合物、制备方法和使用方法 | |
| JP2009526834A5 (enExample) | ||
| WO2010005581A4 (en) | Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) | |
| CN111372579B (zh) | 取代的苯基磺酰基苯基三唑硫酮和其用途 | |
| US10358405B2 (en) | Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases | |
| JP5749176B2 (ja) | トリプル再取込み阻害剤及びそれらの使用方法 | |
| JP7295145B2 (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
| JPWO2019234240A5 (enExample) | ||
| AU2014284304A1 (en) | Method of treating neurodegenerative disorders | |
| CN113316564B (zh) | 一种稠合三环氘代衍生物及其组合物和应用 | |
| JP2008501656A5 (enExample) | ||
| JP7382944B2 (ja) | 神経変性疾患を予防・治療するための新規な化合物及びその応用 | |
| JP2021105061A (ja) | アミロイド線維形成の抑制又は阻害剤 | |
| CN103260614B (zh) | 联合疗法 | |
| JPWO2023196720A5 (enExample) | ||
| JPWO2022051305A5 (enExample) |